scholarly journals DPP4 Gene Polymorphism Associates With Type 2 Diabetes Mellitus in Older Adults

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 123-124
Author(s):  
Elisa Alves ◽  
Audrey Tonet-Furioso ◽  
Izabela D Bastos ◽  
Clayton Moraes ◽  
Otávio Nóbrega
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Older Adults ◽  
Type 2 Diabetes Mellitus ◽  
Glycosylated Hemoglobin ◽  
Federal District ◽  
Genetic Variations ◽  
Community Dwelling ◽  
Dipeptidyl Peptidase 4

Abstract Genetic variations of the dipeptidyl peptidase 4 enzyme (DPP-4) have been associated with glycemic disorders, especially among older adults. The objective of this study was to investigate the association of a single nucleotide polymorphism on the DPP4 gene with the occurrence of type 2 diabetes mellitus in a sample of older community-dwelling patients. Clinical, anthropometric and physiological characteristics as well as biochemical data related to lipidemia, glycemia and hormonal factors and variables related to the lifestyle were analyzed among 338 individuals aged 60 years and older from two general geriatric outpatient clinics in the Federal District, Brazil. Genotypes related to the polymorphism rs3788979 (A/G) of the DPP4 gene of these patients were determined by conventional polymerase chain reaction followed by enzymatic restriction, whereas the serum levels of DPP-4 were assessed by colorimetric immunoassay. Among the results obtained, there was clear variation in the glycemic levels both in terms of blood glucose and glycosylated hemoglobin according to DPP-4 genotypes, with increased levels between homozygotes for the G allele. However, no association was found between genotypes and occurrence of type 2 diabetes mellitus in patients. No other clinical, biochemical or anthropometric variables were influenced by the polymorphism. In our conditions, there was no association between genotypes and DPP-4 levels. Considering that DPP-4 is involved in the metabolism of incretins and directly interferes with glycemia in organisms, our result corroborates that genetic variations of this enzyme can affect glycemic homeostasis, despite not being determinant for the occurrence of type 2 diabetes mellitus.

Type 2 Diabetes Mellitus and Cognitive Decline in Two Large Cohorts of Community-Dwelling Older Adults

2008 ◽  
Vol 56 (6) ◽  
pp. 1028-1036 ◽  
Author(s):  
Olivia I. Okereke ◽  
Jae H. Kang ◽  
Nancy R. Cook ◽  
J. Michael Gaziano ◽  
JoAnn E. Manson ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Older Adults ◽  
Type 2 Diabetes Mellitus ◽  
Cognitive Decline ◽  
Community Dwelling ◽  
Community Dwelling Older Adults

scholarly journals Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials

2012 ◽  
Vol 3 (4) ◽  
pp. 113-124 ◽  
Author(s):  
Janet B. McGill
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hepatic Impairment ◽  
Dose Adjustment ◽  
Glycosylated Hemoglobin ◽  
Development Program ◽  
Postprandial Glucose ◽  
Dipeptidyl Peptidase 4

Patients with type 2 diabetes mellitus (T2DM) frequently require multiple therapies to effectively control hyperglycemia, and many new agents for glucose control have been developed over the past few decades. Linagliptin is a recently approved oral antidiabetic drug that acts by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). Unlike other DPP-4 inhibitors, linagliptin is excreted chiefly via the enterohepatic system, and can be used without dose adjustment in patients with renal or hepatic impairment. Linagliptin was approved by the US Food and Drug Administration based on a large development program, including four pivotal trials in patients with T2DM, assessing the efficacy and safety of linagliptin when used as monotherapy or in combination with other oral antidiabetes drugs. Linagliptin was associated with significant improvements in glycosylated hemoglobin, fasting plasma glucose and postprandial glucose, and more patients receiving linagliptin showed meaningful improvements and achieved targets for glycosylated hemoglobin. Linagliptin was well tolerated, with an adverse event profile similar to that of placebo, and low rates of hypoglycemic events. Taken together, the pivotal trials confirm linagliptin is effective and safe in patients with T2DM: the convenience of oral dosing with no requirement for dose adjustment in patients with renal or hepatic impairment make linagliptin a valuable option when considering therapies for patients with T2DM.

High HBA1C Level Is Associated With Low Heamoglobin Level

2018 ◽  
Vol 3 (02) ◽  
Author(s):  
Mafooza Rashid ◽  
B. K. Gupta, Vinay Bharat ◽  
Abhishek Gupta ◽  
Zubair Rashid
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycosylated Hemoglobin ◽  
Good Control ◽  
Diabetic Control ◽  
Medical College ◽  
High Hba1c ◽  
Normal Controls

Background: The aim of the study was to compare the hemoglobin levels among normal controls (patients) and patients of TypeII diabetes with HbA1c levels below 7 % & above 7 %.and secondly to identify the undetected cases of anemia in TypeII diabetes. Materials & Methods - 50 patients of type 2 diabetes mellitus with their glycosylated hemoglobin levels less than 7 %, 50 patients of type 2 diabetes mellitus with their glycosylated hemoglobin levels more than 7 % attending the Medicine outpatient department of Subharti Medical College and Hospital will be the subjects for the study.50 age and sex matched controls will be selected randomly from Subharti Medical College and Hospital. Informed written consent will be taken from all the subjects. The study will be conducted from January 2016 to January. Result - We studied 50 cases with HbA1C>7(poor control),50 cases with HbA1C 5.6 to7 (good control) and 50 controls with HbA1C ≤5.6, we observed in cases with HbA1C>7 (poorly control) ,the mean HbA1C is 9.9±2 and mean Hb is 9.8±1.3 as compared to cases with HbA1C 5.6 to 7(good control) where mean HbA1C is 6±0.4 and Hb is 13±0.5,this clearly indicates that in cases HbA1C is more Hb levels are low and when HbA1C is less Hb levels are higher. Conclusion - In the present study we found negative correlation between HbA1c & Hb levels. As the value of HbA1c increases, as in cases of HbA1c >7(poor diabetic control), we found low Hb levels as compared to the cases with HbA1c <7(5.6-7) (good control).

Sign in / Sign up

Export Citation Format

Share Document